New hope for AML patients: drug combo trial launches
NCT ID NCT07392814
First seen Feb 06, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This early-phase trial tests adding tocilizumab to standard chemotherapy (venetoclax and azacitidine) for adults with acute myeloid leukemia who cannot undergo intensive treatment. The goal is to find the safest dose and see if the combination improves response. About 12 participants will be enrolled at one hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA ACUTE MYELOID - AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU of Nantes
Nantes, 44000, France
Conditions
Explore the condition pages connected to this study.